NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of$0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.02 per share when it actually produced earnings of$0.04, delivering a surprise of 100%.Over the last four ...